Trial Profile

Vorinostat With Gemcitabine/Clofarabine/Busulfan for Allogeneic Transplantation for Aggressive Lymphomas

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 15 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vorinostat (Primary) ; Busulfan; Clofarabine; Cyclophosphamide; Gemcitabine; Mycophenolate mofetil; Mycophenolate mofetil; Rituximab; Tacrolimus
Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
Focus Therapeutic Use

Most Recent Events

11 Jan 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
29 Jun 2022 Planned initiation date changed from 1 Jun 2020 to 1 Jun 2023.
13 Jan 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com